GSK plc reported 13 positions worth $602.22M for the quarter ended Jun 30, 2026, up 0.5% on the prior quarter. It opened 0 new positions, added to 0, trimmed 0 and exited 0. Its largest holding is CRISPR Therapeutics AG at 29.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
No positions were reduced this quarter.
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRSP CRISPR Therapeutics AG | Healthcare | 3.22M | $175.65M | 29.17% | 0 | 0.0% | Unchanged | 3.33% |
| 2 | WVE Wave Life Sciences, Inc. | Healthcare | 18.25M | $106.01M | 17.6% | 0 | 0.0% | Unchanged | 8.94% |
| 3 | VIR Vir Biotechnology, Inc. | Healthcare | 8.55M | $87.13M | 14.47% | 0 | 0.0% | Unchanged | 5.05% |
| 4 | BNTX BioNTech SE | Healthcare | 889.8K | $82.80M | 13.75% | 0 | 0.0% | Unchanged | 0.37% |
| 5 | IDYA IDEAYA Biosciences, Inc. | Healthcare | 1.33M | $49.69M | 8.25% | 0 | 0.0% | Unchanged | 1.38% |
| 6 | CYTK Cytokinetics Inc | Healthcare | 340.4K | $29.00M | 4.82% | 0 | 0.0% | Unchanged | 0.24% |
| 7 | LYEL Lyell Immunopharma, Inc. | Healthcare | 1.51M | $21.25M | 3.53% | 0 | 0.0% | Unchanged | 6.47% |
| 8 | SPRO Spero Therapeutics, Inc. | Healthcare | 9.19M | $20.31M | 3.37% | 0 | 0.0% | Unchanged | 15.81% |
| 9 | NKTX Nkarta, Inc. | Healthcare | 3.15M | $8.92M | 1.48% | 0 | 0.0% | Unchanged | 4.23% |
| 10 | FULC Fulcrum Therapeutics, Inc. | Healthcare | 1.79M | $6.54M | 1.09% | 0 | 0.0% | Unchanged | 2.34% |
| 11 | BCYC Bicycle Therapeutics Plc | Healthcare | 1.53M | $6.49M | 1.08% | 0 | 0.0% | Unchanged | 2.19% |
| 12 | CVRX CVRx, Inc. | Healthcare | 1.01M | $5.18M | 0.86% | 0 | 0.0% | Unchanged | 3.78% |
| 13 | RGNX REGENXBIO Inc. | Healthcare | 271.5K | $3.25M | 0.54% | 0 | 0.0% | Unchanged | 0.5% |
Tip. Select a row to see that position’s full history at Gsk.
As of its Q2 2026 13F filing, GSK plc’s five largest positions were CRISPR Therapeutics AG (CRSP) at 29.2%, Wave Life Sciences, Inc. (WVE) at 17.6%, Vir Biotechnology, Inc. (VIR) at 14.5%, BioNTech SE (BNTX) at 13.7%, IDEAYA Biosciences, Inc. (IDYA) at 8.3% of the reported portfolio.
GSK plc reported a 13F portfolio worth $602.22M across 13 positions for Q2 2026. That is up 0.5% from the previous quarter.
From the Form 13F-HR reports GSK plc files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.